1 Supply Summary

• 1.1 Hemato Oncology Testing Introduction
• 1.2 World Hemato Oncology Testing Market Size & Forecast (2021 & 2025 & 2032)
• 1.3 World Hemato Oncology Testing Total Market by Region (by Headquarter Location)
  • 1.3.1 World Hemato Oncology Testing Market Size by Region (2021-2032), (by Headquarter Location)
  • 1.3.2 United States Based Company Hemato Oncology Testing Revenue (2021-2032)
  • 1.3.3 China Based Company Hemato Oncology Testing Revenue (2021-2032)
  • 1.3.4 Europe Based Company Hemato Oncology Testing Revenue (2021-2032)
  • 1.3.5 Japan Based Company Hemato Oncology Testing Revenue (2021-2032)
  • 1.3.6 South Korea Based Company Hemato Oncology Testing Revenue (2021-2032)
  • 1.3.7 ASEAN Based Company Hemato Oncology Testing Revenue (2021-2032)
  • 1.3.8 India Based Company Hemato Oncology Testing Revenue (2021-2032)
• 1.4 Market Drivers, Restraints and Trends
  • 1.4.1 Hemato Oncology Testing Market Drivers
  • 1.4.2 Factors Affecting Demand
  • 1.4.3 Major Market Trends

2 Demand Summary

• 2.1 World Hemato Oncology Testing Consumption Value (2021-2032)
• 2.2 World Hemato Oncology Testing Consumption Value by Region
  • 2.2.1 World Hemato Oncology Testing Consumption Value by Region (2021-2026)
  • 2.2.2 World Hemato Oncology Testing Consumption Value Forecast by Region (2027-2032)
• 2.3 United States Hemato Oncology Testing Consumption Value (2021-2032)
• 2.4 China Hemato Oncology Testing Consumption Value (2021-2032)
• 2.5 Europe Hemato Oncology Testing Consumption Value (2021-2032)
• 2.6 Japan Hemato Oncology Testing Consumption Value (2021-2032)
• 2.7 South Korea Hemato Oncology Testing Consumption Value (2021-2032)
• 2.8 ASEAN Hemato Oncology Testing Consumption Value (2021-2032)
• 2.9 India Hemato Oncology Testing Consumption Value (2021-2032)

3 World Hemato Oncology Testing Companies Competitive Analysis

• 3.1 World Hemato Oncology Testing Revenue by Player (2021-2026)
• 3.2 Industry Rank and Concentration Rate (CR)
  • 3.2.1 Global Hemato Oncology Testing Industry Rank of Major Players
  • 3.2.2 Global Concentration Ratios (CR4) for Hemato Oncology Testing in 2025
  • 3.2.3 Global Concentration Ratios (CR8) for Hemato Oncology Testing in 2025
• 3.3 Hemato Oncology Testing Company Evaluation Quadrant
• 3.4 Hemato Oncology Testing Market: Overall Company Footprint Analysis
  • 3.4.1 Hemato Oncology Testing Market: Region Footprint
  • 3.4.2 Hemato Oncology Testing Market: Company Product Type Footprint
  • 3.4.3 Hemato Oncology Testing Market: Company Product Application Footprint
• 3.5 Competitive Environment
  • 3.5.1 Historical Structure of the Industry
  • 3.5.2 Barriers of Market Entry
  • 3.5.3 Factors of Competition
• 3.6 Mergers & Acquisitions Activity

4 United States VS China VS Rest of World (by Headquarter Location)

• 4.1 United States VS China: Hemato Oncology Testing Revenue Comparison (by Headquarter Location)
  • 4.1.1 United States VS China: Hemato Oncology Testing Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
  • 4.1.2 United States VS China: Hemato Oncology Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
• 4.2 United States Based Companies VS China Based Companies: Hemato Oncology Testing Consumption Value Comparison
  • 4.2.1 United States VS China: Hemato Oncology Testing Consumption Value Comparison (2021 & 2025 & 2032)
  • 4.2.2 United States VS China: Hemato Oncology Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
• 4.3 United States Based Hemato Oncology Testing Companies and Market Share, 2021-2026
  • 4.3.1 United States Based Hemato Oncology Testing Companies, Headquarters (States, Country)
  • 4.3.2 United States Based Companies Hemato Oncology Testing Revenue, (2021-2026)
• 4.4 China Based Companies Hemato Oncology Testing Revenue and Market Share, 2021-2026
  • 4.4.1 China Based Hemato Oncology Testing Companies, Company Headquarters (Province, Country)
  • 4.4.2 China Based Companies Hemato Oncology Testing Revenue, (2021-2026)
• 4.5 Rest of World Based Hemato Oncology Testing Companies and Market Share, 2021-2026
  • 4.5.1 Rest of World Based Hemato Oncology Testing Companies, Headquarters (Province, Country)
  • 4.5.2 Rest of World Based Companies Hemato Oncology Testing Revenue (2021-2026)

5 Market Analysis by Type

• 5.1 World Hemato Oncology Testing Market Size Overview by Type: 2021 VS 2025 VS 2032
• 5.2 Segment Introduction by Type
  • 5.2.1 ctDNA Testing
  • 5.2.2 CTC Testing
  • 5.2.3 Other Testing
• 5.3 Market Segment by Type
  • 5.3.1 World Hemato Oncology Testing Market Size by Type (2021-2026)
  • 5.3.2 World Hemato Oncology Testing Market Size by Type (2027-2032)
  • 5.3.3 World Hemato Oncology Testing Market Size Market Share by Type (2027-2032)

6 Market Analysis by Application

• 6.1 World Hemato Oncology Testing Market Size Overview by Application: 2021 VS 2025 VS 2032
• 6.2 Segment Introduction by Application
  • 6.2.1 Hospital
  • 6.2.2 Third Party Agency
  • 6.2.3 Others
• 6.3 Market Segment by Application
  • 6.3.1 World Hemato Oncology Testing Market Size by Application (2021-2026)
  • 6.3.2 World Hemato Oncology Testing Market Size by Application (2027-2032)
  • 6.3.3 World Hemato Oncology Testing Market Size Market Share by Application (2021-2032)

7 Company Profiles

• 7.1 Roche
  • 7.1.1 Roche Details
  • 7.1.2 Roche Major Business
  • 7.1.3 Roche Hemato Oncology Testing Product and Services
  • 7.1.4 Roche Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.1.5 Roche Recent Developments/Updates
  • 7.1.6 Roche Competitive Strengths & Weaknesses
• 7.2 Berry Genomics
  • 7.2.1 Berry Genomics Details
  • 7.2.2 Berry Genomics Major Business
  • 7.2.3 Berry Genomics Hemato Oncology Testing Product and Services
  • 7.2.4 Berry Genomics Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.2.5 Berry Genomics Recent Developments/Updates
  • 7.2.6 Berry Genomics Competitive Strengths & Weaknesses
• 7.3 Burning Rock Dx
  • 7.3.1 Burning Rock Dx Details
  • 7.3.2 Burning Rock Dx Major Business
  • 7.3.3 Burning Rock Dx Hemato Oncology Testing Product and Services
  • 7.3.4 Burning Rock Dx Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.3.5 Burning Rock Dx Recent Developments/Updates
  • 7.3.6 Burning Rock Dx Competitive Strengths & Weaknesses
• 7.4 BGI
  • 7.4.1 BGI Details
  • 7.4.2 BGI Major Business
  • 7.4.3 BGI Hemato Oncology Testing Product and Services
  • 7.4.4 BGI Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.4.5 BGI Recent Developments/Updates
  • 7.4.6 BGI Competitive Strengths & Weaknesses
• 7.5 Genetron
  • 7.5.1 Genetron Details
  • 7.5.2 Genetron Major Business
  • 7.5.3 Genetron Hemato Oncology Testing Product and Services
  • 7.5.4 Genetron Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.5.5 Genetron Recent Developments/Updates
  • 7.5.6 Genetron Competitive Strengths & Weaknesses
• 7.6 Haplox
  • 7.6.1 Haplox Details
  • 7.6.2 Haplox Major Business
  • 7.6.3 Haplox Hemato Oncology Testing Product and Services
  • 7.6.4 Haplox Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.6.5 Haplox Recent Developments/Updates
  • 7.6.6 Haplox Competitive Strengths & Weaknesses
• 7.7 Amoy Dx
  • 7.7.1 Amoy Dx Details
  • 7.7.2 Amoy Dx Major Business
  • 7.7.3 Amoy Dx Hemato Oncology Testing Product and Services
  • 7.7.4 Amoy Dx Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.7.5 Amoy Dx Recent Developments/Updates
  • 7.7.6 Amoy Dx Competitive Strengths & Weaknesses
• 7.8 Genosaber
  • 7.8.1 Genosaber Details
  • 7.8.2 Genosaber Major Business
  • 7.8.3 Genosaber Hemato Oncology Testing Product and Services
  • 7.8.4 Genosaber Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.8.5 Genosaber Recent Developments/Updates
  • 7.8.6 Genosaber Competitive Strengths & Weaknesses
• 7.9 YZY Biopharma
  • 7.9.1 YZY Biopharma Details
  • 7.9.2 YZY Biopharma Major Business
  • 7.9.3 YZY Biopharma Hemato Oncology Testing Product and Services
  • 7.9.4 YZY Biopharma Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.9.5 YZY Biopharma Recent Developments/Updates
  • 7.9.6 YZY Biopharma Competitive Strengths & Weaknesses
• 7.10 Wondfo
  • 7.10.1 Wondfo Details
  • 7.10.2 Wondfo Major Business
  • 7.10.3 Wondfo Hemato Oncology Testing Product and Services
  • 7.10.4 Wondfo Hemato Oncology Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 7.10.5 Wondfo Recent Developments/Updates
  • 7.10.6 Wondfo Competitive Strengths & Weaknesses

8 Industry Chain Analysis

• 8.1 Hemato Oncology Testing Industry Chain
• 8.2 Hemato Oncology Testing Upstream Analysis
• 8.3 Hemato Oncology Testing Midstream Analysis
• 8.4 Hemato Oncology Testing Downstream Analysis

9 Research Findings and Conclusion

10 Appendix

• 10.1 Methodology
• 10.2 Research Process and Data Source

The global Hemato Oncology Testing market size is expected to reach $ million by 2032, rising at a market growth of %CAGR during the forecast period (2026-2032).
Hemato Oncology Testing is a technology to predict the probability of disease by collecting genes (DNA) in human blood and analyzing and measuring the complete sequence of genes. Genetic testing can identify individuals" genes for disease, thereby preventing or treating tumours earlier.
Hematologic tumor detection is a technique to detect tumor genes on the basis of gene detection. Blood tumor detection services cover a wide range of solid tumors such as lung cancer, breast cancer, stomach cancer, esophageal cancer, colorectal cancer and liver cancer. Common tumors are detected. According to different tumor stages, blood tumor detection can be divided into four categories: tumor susceptibility gene screening, tumor early diagnosis, tumor individualized drug diagnosis, and tumor recovery monitoring. Tumor susceptibility gene screening can help people at high risk of genetic mutations to actively prevent tumors. Early diagnosis of cancer can help patients to find the disease as early as possible, thus greatly improving the survival rate of cancer patients. Individualized drug diagnosis for cancer patients to provide a more accurate cancer treatment program. Tumor recovery was monitored to assess the risk of recurrence.
In this paper, the current status and future development trend of hematoncology testing in China market are studied, focusing on the analysis of the companies that play an important role in the Chinese market, and focusing on the revenue, market share, market positioning, development plans, products and services of these companies in the Chinese market.
In Chinese Market, Hemato Oncology Testing key players include Roche, Berry Genomics, Burning Rock Dx, BGI, Genetron, etc. Global top 5 manufacturers hold a share over 28%.
In terms of product, ctDNA Testing is the largest segment, with a share over 71%. And in terms of application, the largest application is Hospital, followed by Third Party Agency, Others.
This report studies the global Hemato Oncology Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Hemato Oncology Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hemato Oncology Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Hemato Oncology Testing total market, 2021-2032, (USD Million)
Global Hemato Oncology Testing total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Hemato Oncology Testing total market, key domestic companies, and share, (USD Million)
Global Hemato Oncology Testing revenue by player, revenue and market share 2021-2026, (USD Million)
Global Hemato Oncology Testing total market by Type, CAGR, 2021-2032, (USD Million)
Global Hemato Oncology Testing total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Hemato Oncology Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Berry Genomics, Burning Rock Dx, BGI, Genetron, Haplox, Amoy Dx, Genosaber, YZY Biopharma, Wondfo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Hemato Oncology Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Hemato Oncology Testing Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Hemato Oncology Testing Market, Segmentation by Type:
ctDNA Testing
CTC Testing
Other Testing
Global Hemato Oncology Testing Market, Segmentation by Application:
Hospital
Third Party Agency
Others
Companies Profiled:
Roche
Berry Genomics
Burning Rock Dx
BGI
Genetron
Haplox
Amoy Dx
Genosaber
YZY Biopharma
Wondfo
Key Questions Answered
1. How big is the global Hemato Oncology Testing market?
2. What is the demand of the global Hemato Oncology Testing market?
3. What is the year over year growth of the global Hemato Oncology Testing market?
4. What is the total value of the global Hemato Oncology Testing market?
5. Who are the Major Players in the global Hemato Oncology Testing market?
6. What are the growth factors driving the market demand?